tacrolimus

Tacrolimus is a lipid of Polyketides (PK) class. Tacrolimus is associated with abnormalities such as Renal glomerular disease. The involved functions are known as inhibitors, Fungicidal activity, Metabolic Inhibition, Excretory function and Dephosphorylation. Tacrolimus often locates in Hepatic, Mitochondrial matrix and Inner mitochondrial membrane. The associated genes with Tacrolimus are RHOA gene and BGN gene.

Cross Reference

Introduction

To understand associated biological information of tacrolimus, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.

What diseases are associated with tacrolimus?

tacrolimus is suspected in Renal glomerular disease, Candidiasis, Mycoses, PARKINSON DISEASE, LATE-ONSET, Morphologically altered structure, Skin Diseases, Infectious and other diseases in descending order of the highest number of associated sentences.

Related references are mostly published in these journals:

Disease Cross reference Weighted score Related literature
Loading... please refresh the page if content is not showing up.

Possible diseases from mapped MeSH terms on references

We collected disease MeSH terms mapped to the references associated with tacrolimus

MeSH term MeSH ID Detail
Brain Diseases D001927 27 associated lipids
Endotoxemia D019446 27 associated lipids
Autoimmune Diseases D001327 27 associated lipids
Encephalomyelitis, Autoimmune, Experimental D004681 26 associated lipids
Pseudomonas Infections D011552 25 associated lipids
Cerebrovascular Disorders D002561 25 associated lipids
Ascites D001201 25 associated lipids
Leukemia-Lymphoma, Adult T-Cell D015459 25 associated lipids
Genetic Predisposition to Disease D020022 24 associated lipids
Colitis, Ulcerative D003093 24 associated lipids
Per page 10 20 50 100 | Total 613

PubChem Associated disorders and diseases

What pathways are associated with tacrolimus

There are no associated biomedical information in the current reference collection.

PubChem Biomolecular Interactions and Pathways

Link to PubChem Biomolecular Interactions and Pathways

What cellular locations are associated with tacrolimus?

Related references are published most in these journals:

Location Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What functions are associated with tacrolimus?


Related references are published most in these journals:

Function Cross reference Weighted score Related literatures

What lipids are associated with tacrolimus?

Related references are published most in these journals:

Lipid concept Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What genes are associated with tacrolimus?

Related references are published most in these journals:


Gene Cross reference Weighted score Related literatures

What common seen animal models are associated with tacrolimus?

There are no associated biomedical information in the current reference collection.

NCBI Entrez Crosslinks

All references with tacrolimus

Download all related citations
Per page 10 20 50 100 | Total 15051
Authors Title Published Journal PubMed Link
Whalen HR et al. High Intrapatient Tacrolimus Variability Is Associated With Worse Outcomes in Renal Transplantation Using a Low-Dose Tacrolimus Immunosuppressive Regime. 2017 Transplantation pmid:26950724
Morrissey PE Prope tolerance: is it the end or the means? 2009 Transplantation pmid:19502973
Farid SG et al. Alemtuzumab (Campath-1H)-induced coagulopathy in renal transplantation. 2009 Transplantation pmid:19502974
Shin BH et al. Regulation of anti-HLA antibody-dependent natural killer cell activation by immunosuppressive agents. 2014 Transplantation pmid:24342979
Egawa H et al. FK506 conversion therapy in pediatric liver transplantation. 1994 Transplantation pmid:7513911
Yoon SH et al. CYP3A and ABCB1 genetic polymorphisms on the pharmacokinetics and pharmacodynamics of tacrolimus and its metabolites (M-I and M-III). 2013 Transplantation pmid:23364483
Cvetkovic M et al. The deleterious effects of long-term cyclosporine A, cyclosporine G, and FK506 on bone mineral metabolism in vivo. 1994 Transplantation pmid:7513912
Nakamura Y et al. Acceptance of islet allografts in the liver of mice by blockade of an inducible costimulator. 2003 Transplantation pmid:12717187
Yang CW et al. Pharmacological preconditioning with low-dose cyclosporine or FK506 reduces subsequent ischemia/reperfusion injury in rat kidney. 2001 Transplantation pmid:11740384
Benito N et al. Alternariosis after liver transplantation. 2001 Transplantation pmid:11740399
Boukriche Y et al. Severe axonal polyneuropathy after a FK506 overdosage in a lung transplant recipient. 2001 Transplantation pmid:11740402
Hodge G et al. Lymphocytic bronchiolitis is associated with inadequate suppression of blood T-cell granzyme B, IFN-gamma, and TNF-alpha. 2010 Transplantation pmid:20559033
Yun J et al. Bilateral ischemic optic neuropathy in a patient using tacrolimus (FK506) after liver transplantation. 2010 Transplantation pmid:20559109
Schäffer MR et al. Tacrolimus impairs wound healing: a possible role of decreased nitric oxide synthesis. 1998 Transplantation pmid:9539093
Anderson PO Tacrolimus and breastfeeding. 1998 Transplantation pmid:9539100
Berenguer M et al. Effect of calcineurin inhibitors in the outcome of liver transplantation in hepatitis C virus-positive recipients. 2010 Transplantation pmid:21068701
Weir MR et al. Long-term Follow-up of Kidney Transplant Recipients in the Spare-the-Nephron-Trial. 2017 Transplantation pmid:26950714
Firdaous I et al. Pediatric intravenous FK506--how much are we really infusing? 1994 Transplantation pmid:7517079
Manez R et al. Rejection and hepatitis in liver transplants. 1994 Transplantation pmid:7517080
Ueno P et al. Wound Healing Complications in Kidney Transplant Recipients Receiving Everolimus. 2017 Transplantation pmid:27490418
Cao W et al. Effects of rapamycin on growth factor-stimulated vascular smooth muscle cell DNA synthesis. Inhibition of basic fibroblast growth factor and platelet-derived growth factor action and antagonism of rapamycin by FK506. 1995 Transplantation pmid:7532879
Murase N et al. Suppression of allograft rejection with FK506. I. Prolonged cardiac and liver survival in rats following short-course therapy. 1990 Transplantation pmid:1696405
Propper DJ et al. FK506--its influence on anti-class 1 MHC alloantibody responses to blood transfusions. 1990 Transplantation pmid:1696409
Soccal PM et al. Improvement of drug-induced chronic renal failure in lung transplantation. 1999 Transplantation pmid:10428288
Lee CM et al. Outcomes in diabetic patients after simultaneous pancreas-kidney versus kidney alone transplantation. 1997 Transplantation pmid:9371670
Migita K et al. FK506 potentiates steroid-induced T-cell apoptosis. 1997 Transplantation pmid:9371682
Dhar DK et al. Effective prevention of ischemic injury of the dearterialized canine liver by FK506 pretreatment. 1993 Transplantation pmid:7506456
Fabrega AJ et al. Enhancement of allograft survival by single intraoperative donor-specific blood transfusion combined with FK506. 1993 Transplantation pmid:7506458
Nicolai S and Bunyavanich S Hypersensitivity reaction to intravenous but not oral tacrolimus. 2012 Transplantation pmid:23128975
Jain A et al. FK506 and pregnancy in liver transplant patients. 1993 Transplantation pmid:7506459
Sankary HN et al. FK506 treatment in combination with leflunomide in hamster-to-rat heart and liver xenograft transplantation. 1998 Transplantation pmid:9798690
Burke MD et al. Inhibition of the metabolism of cyclosporine by human liver microsomes by FK506. 1990 Transplantation pmid:1700507
Sharif A et al. Insulin resistance indexes in renal transplant recipients maintained on tacrolimus immunosuppression. 2010 Transplantation pmid:20145524
Koh A et al. Supplemental islet infusions restore insulin independence after graft dysfunction in islet transplant recipients. 2010 Transplantation pmid:20145529
Sofi AA et al. Bullous pemphigoid associated with acute renal allograft rejection. 2010 Transplantation pmid:20145531
Butani L et al. Amelioration of tacrolimus-induced nephrotoxicity in rats using juniper oil. 2003 Transplantation pmid:12883183
Ito A et al. Donor-specific tolerance by perioperative intrathymic injection of bone marrow cells in the rat cardiac allograft model: use of FK506 can shorten the necessary duration of pretransplant intrathymic conditioning. 1997 Transplantation pmid:9311715
David-Neto E et al. Longitudinal Pharmacokinetics of Tacrolimus in Elderly Compared With Younger Recipients in the First 6 Months After Renal Transplantation. 2017 Transplantation pmid:27482958
Marcén R et al. Lumbar bone mineral density in renal transplant patients on neoral and tacrolimus: a four-year prospective study. 2006 Transplantation pmid:16570003
Ciancio G et al. A randomized long-term trial of tacrolimus/sirolimus versus tacrolimums/mycophenolate versus cyclosporine/sirolimus in renal transplantation: three-year analysis. 2006 Transplantation pmid:16570006
Barten MJ et al. Synergistic effects of sirolimus with cyclosporine and tacrolimus: analysis of immunosuppression on lymphocyte proliferation and activation in rat whole blood. 2004 Transplantation pmid:15114077
Sood P et al. Management and outcome of BK viremia in renal transplant recipients: a prospective single-center study. 2012 Transplantation pmid:23018881
Moutabarrik A et al. FK506-induced kidney tubular cell injury. 1992 Transplantation pmid:1281562
Vennarecci G et al. Apoptosis and rejection in rat intestinal transplantation: correlation with FK506 doses and donor specific bone marrow infusions. 2001 Transplantation pmid:11455248
Schulman SL et al. Interaction between tacrolimus and chloramphenicol in a renal transplant recipient. 1998 Transplantation pmid:9625026
Pruvot FR and Noel C Comment on "Pregnancy after liver transplantation under tacrolimus" by Jain et al. 1998 Transplantation pmid:9625033
Shackleton CR et al. Lack of correlation between the magnitude of preservation injury and the incidence of acute rejection, need for OKT3, and conversion to FK506 in cyclosporine-treated primary liver allograft recipients. 1995 Transplantation pmid:7570950
Shimada T et al. Lowered blood concentration of tacrolimus and its recovery with changes in expression of CYP3A and P-glycoprotein after high-dose steroid therapy. 2002 Transplantation pmid:12451243
Bolin P et al. Optimizing tacrolimus therapy in the maintenance of renal allografts: 12-month results. 2008 Transplantation pmid:18622283
Herlenius G et al. Chronic kidney disease--a common and serious complication after intestinal transplantation. 2008 Transplantation pmid:18622286
Ceulemans LJ et al. Nonsteroidal anti-inflammatory drug-induced intestinal graft loss 12 years after transplantation. 2015 Transplantation pmid:25695790
Watson MJ et al. Renal function impacts outcomes after intestinal transplantation. 2008 Transplantation pmid:18622288
Uemura T et al. Single dose of alemtuzumab induction with steroid-free maintenance immunosuppression in pancreas transplantation. 2011 Transplantation pmid:21841541
Aw MM et al. Calcineurin-inhibitor related nephrotoxicity- reversibility in paediatric liver transplant recipients. 2001 Transplantation pmid:11544444
Terakura M et al. Lymphoid/nonlymphoid compartmentalization of donor leukocyte chimerism in rat recipients of heart allografts, with or without adjunct bone marrow. 1998 Transplantation pmid:9721804
Glicklich D et al. Chronic renal allograft rejection: no response to mycophenolate mofetil. 1998 Transplantation pmid:9721811
Calandra S Sinus arrest during tacrolimus treatment: was the QT interval prolonged? 1998 Transplantation pmid:9721813
Jacobson PA et al. Novel polymorphisms associated with tacrolimus trough concentrations: results from a multicenter kidney transplant consortium. 2011 Transplantation pmid:21206424
Richards KR et al. Tacrolimus trough level at discharge predicts acute rejection in moderately sensitized renal transplant recipients. 2014 Transplantation pmid:24784360
Nolan TJ and Schad GA Tacrolimus allows autoinfective development of the parasitic nematode Strongyloides stercoralis. 1996 Transplantation pmid:8878405
Chung BH et al. Suppressive Effect of 1α,25-Dihydroxyvitamin D3 on Th17-Immune Responses in Kidney Transplant Recipients With Tacrolimus-Based Immunosuppression. 2017 Transplantation pmid:28107277
Klupp J et al. Indications of mycophenolate mofetil in liver transplantation. 2005 Transplantation pmid:16286893
Eckhoff DE et al. The safety and efficacy of a two-dose daclizumab (zenapax) induction therapy in liver transplant recipients. 2000 Transplantation pmid:10830224
Nakata Y et al. Tacrolimus and myocardial hypertrophy. 2000 Transplantation pmid:10830241
Ji E et al. Combinational effect of intestinal and hepatic CYP3A5 genotypes on tacrolimus pharmacokinetics in recipients of living donor liver transplantation. 2012 Transplantation pmid:22992768
Fukushima D et al. Epstein-Barr virus--associated posttransplantation lymphoproliferative disorder with tacrolimus metabolism deterioration in infants after living-donor liver transplantation. 2015 Transplantation pmid:24846306
Opelz G and Döhler B Influence of immunosuppressive regimens on graft survival and secondary outcomes after kidney transplantation. 2009 Transplantation pmid:19300179
Rostambeigi N et al. Unique cellular and mitochondrial defects mediate FK506-induced islet β-cell dysfunction. 2011 Transplantation pmid:21200364
Klein A et al. Impact of a pharmaceutical care program on liver transplant patients' compliance with immunosuppressive medication: a prospective, randomized, controlled trial using electronic monitoring. 2009 Transplantation pmid:19300186
Beckebaum S et al. Predictive factors of outcome in patients transplanted for hepatitis B. 2009 Transplantation pmid:19300191
Jordan ML et al. Tacrolimus rescue therapy for renal allograft rejection--five-year experience. 1997 Transplantation pmid:9020321
Mazariegos GV et al. Weaning of immunosuppression in liver transplant recipients. 1997 Transplantation pmid:9020325
Marin-Casino M et al. Significant tacrolimus and dronedarone interaction in a kidney transplant recipient. 2014 Transplantation pmid:25243519
Marks WH et al. Asialoglycoprotein/asialoglycoprotein receptor (AGP-AGPr) interaction is an important mechanism for the uptake of FK506 by hepatocytes. 1997 Transplantation pmid:9020333
Pascual J et al. Authors' reply: cyclosporine A versus tacrolimus in steroid withdrawal strategies. 2011 Transplantation pmid:21336083
Hardinger KL et al. A randomized, prospective, pharmacoeconomic trial of tacrolimus versus cyclosporine in combination with thymoglobulin in renal transplant recipients. 2005 Transplantation pmid:16003231
Egli A et al. Comparison of the effect of standard and novel immunosuppressive drugs on CMV-specific T-cell cytokine profiling. 2013 Transplantation pmid:23274966
Ericzon BG et al. FK506-induced impairment of glucose metabolism in the primate--studies in pancreatic transplant recipients and in nontransplanted animals. 1992 Transplantation pmid:1384189
Wennberg L et al. The efficacy of CD40 ligand blockade in discordant pig-to-rat islet xenotransplantation is correlated with an immunosuppressive effect of immunoglobulin. 2005 Transplantation pmid:15665763
Hebert MF et al. Interpreting tacrolimus concentrations during pregnancy and postpartum. 2013 Transplantation pmid:23274970
Fujishiro J et al. Immunologic benefits of longer graft in rat allogenic small bowel transplantation. 2005 Transplantation pmid:15665767
Pascual J et al. Steroid withdrawal in renal transplant patients on triple therapy with a calcineurin inhibitor and mycophenolate mofetil: a meta-analysis of randomized, controlled trials. 2004 Transplantation pmid:15599321
Farley DE et al. The effect of two new immunosuppressive agents, FK506 and didemnin B, in murine pregnancy. 1991 Transplantation pmid:1713360
Thai NL et al. Alemtuzumab induction and tacrolimus monotherapy in pancreas transplantation: One- and two-year outcomes. 2006 Transplantation pmid:17198247
Thai NL et al. Pancreas transplantation under alemtuzumab (Campath-1H) and tacrolimus: Correlation between low T-cell responses and infection. 2006 Transplantation pmid:17198253
Kainz A et al. Review of the course and outcome of 100 pregnancies in 84 women treated with tacrolimus. 2000 Transplantation pmid:11152103
Nakazawa Y et al. Relationship between in vivo FK506 clearance and in vitro 13-demethylation activity in living-related liver transplantation. 1998 Transplantation pmid:9808496
Krähenbühl S et al. Serious interaction between mibefradil and tacrolimus. 1998 Transplantation pmid:9808502
Tsamandas AC et al. Central venulitis in the allograft liver: a clinicopathologic study. 1997 Transplantation pmid:9256183
Meiser BM et al. Tacrolimus or cyclosporine: which is the better partner for mycophenolate mofetil in heart transplant recipients? 2004 Transplantation pmid:15446320
Jordan ML et al. FK506 "rescue" for resistant rejection of renal allografts under primary cyclosporine immunosuppression. 1994 Transplantation pmid:7512293
Peduto G et al. Long-term host unresponsiveness to encapsulated xenogeneic myoblasts after transient immunosuppression. 2000 Transplantation pmid:10919579
Kashu Y et al. The effect of combination splenectomy and low-dose FK506 therapy on graft survival after liver allograft transplantation in rats. 1996 Transplantation pmid:8633382
Aisa Y et al. Effects of immunosuppressive agents on magnesium metabolism early after allogeneic hematopoietic stem cell transplantation. 2005 Transplantation pmid:16278584
Yoshimura N et al. A case report of pregnancy in renal transplant recipient treated with FK506 (tacrolimus). 1996 Transplantation pmid:8633388
Vítko S et al. Two corticosteroid-free regimens-tacrolimus monotherapy after basiliximab administration and tacrolimus/mycophenolate mofetil-in comparison with a standard triple regimen in renal transplantation: results of the Atlas study. 2005 Transplantation pmid:16378069
Vacher-Coponat H et al. A randomized trial with steroids and antithymocyte globulins comparing cyclosporine/azathioprine versus tacrolimus/mycophenolate mofetil (CATM2) in renal transplantation. 2012 Transplantation pmid:22228415
Tanaka J et al. The immunosuppressive agent FK506 enhances the cytolytic activity of inhibitory natural killer cell receptor (CD94/NKG2A)-expressing CD8 T cells. 2005 Transplantation pmid:16378079
Wang HD et al. Desensitization and Prevention of Antibody-Mediated Rejection in Vascularized Composite Allotransplantation by Syngeneic Hematopoietic Stem Cell Transplantation. 2018 Transplantation pmid:29298238
Dharancy S et al. Elevated interleukin-4 expression in severe recurrent hepatitis C virus after liver transplantation. 2007 Transplantation pmid:17460561